A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.
The patient and/or guardian must voluntarily sign and date a written informed co... [+11]
Any active autoimmune disease, or a history of autoimmune disease requiring syst... [+11]